Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer

References

• SiegelRLMillerKDJemalACancer statisticsCA Cancer J Clin2016201666730
   Google Scholar
• SiegelRLMillerKDJemalACancer statisticsCA Cancer J Clin2017201767730
   Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• ZhuXJuXCaoFSafety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trialBMJ Open2016612e013220
   PubMed Web of Science ®Google Scholar
• ZhuXLiFJuXPrognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancerCancer Med20176102263227028834410
   PubMed Web of Science ®Google Scholar
• VermaVLazenbyAJZhengDDosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trialRadiother Oncol2017122346446928089484
   PubMed Web of Science ®Google Scholar
• BenedictSHYeniceKMFollowillDStereotactic body radiation therapy: the report of AAPM Task Group 101Med Phys20103784078410120879569
   PubMed Web of Science ®Google Scholar
• UenoHOkusakaTIkedaMTakezakoYMorizaneCAn early phase II study of S-1 in patients with metastatic pancreatic cancerOncology2005682–317117816006754
   PubMed Web of Science ®Google Scholar
• UenoHIokaTIkedaMRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST studyJ Clin Oncol201331131640164823547081
   PubMed Web of Science ®Google Scholar
• MorizaneCOkusakaTFuruseJA phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancerCancer Chemother Pharmacol200963231331918398614
   PubMed Web of Science ®Google Scholar
• SudoKYamaguchiTNakamuraKPhase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancerCancer Chemother Pharmacol201167224925420352216
   PubMed Web of Science ®Google Scholar
• KharofaJTsaiSKellyTNeoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancerRadiother Oncol20141131414625443499
   PubMed Web of Science ®Google Scholar
• CoxJDStetzJPajakTFToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)Int J Radiat Oncol Biol Phys1995315134113467713792
   PubMed Web of Science ®Google Scholar
• QiQZhuangLShenYA novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapyCancer2016122142158216727152949
   PubMed Web of Science ®Google Scholar
• LeeSHChungMJKimBThe significance of the prognostic nutritional index for all stages of pancreatic cancerNutr Cancer201769351251927967240
   PubMed Web of Science ®Google Scholar
• GengYQiQSunMChenHWangPChenZPrognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancerEur J Surg Oncol201541111508151426343824
   PubMed Web of Science ®Google Scholar
• CharlsonMSzatrowskiTPPetersonJGoldJValidation of a combined comorbidity indexJ Clin Epidemiol19944711124512517722560
   PubMed Web of Science ®Google Scholar
• Dias-SantosDFerroneCRZhengHLillemoeKDFernándezdel CastilloCThe Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancerSurgery2015157588188725704415
   PubMed Web of Science ®Google Scholar
• FerroneCRFinkelsteinDMThayerSPMuzikanskyAFernandez-DelcastilloCWarshawALPerioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinomaJ Clin Oncol200624182897290216782929
   PubMed Web of Science ®Google Scholar
• von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol201129344548455421969517
   PubMed Web of Science ®Google Scholar
• CloydJMWangHEggerMEAssociation of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinomaJAMA Surg2017152111048105628700784
   PubMed Web of Science ®Google Scholar
• WangXSMendozaTRGaoSZCleelandCSThe Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer painPain1996672–34074168951936
   PubMed Web of Science ®Google Scholar
• LuoNLiMLiuGGDeveloping the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approachQual Life Res201322488589022622627
   PubMed Web of Science ®Google Scholar
• FischerDStewartALBlochDACapturing the patient’s view of change as a clinical outcome measureJAMA1999282121157116210501119
   PubMed Web of Science ®Google Scholar
• OettleHProgress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedsideCancer Treat Rev20144091039104725087471
   PubMed Web of Science ®Google Scholar
• KristensenAVagnildhaugOMGrønbergBHKaasaSLairdBSolheimTSDoes chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic reviewCrit Rev Oncol Hematol20169928629826819138
   PubMed Web of Science ®Google Scholar
• BezjakATuDSeymourLSymptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol200624243831383716921034
   PubMed Web of Science ®Google Scholar
• AuHJKarapetisCSO’CallaghanCJHealth-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 TrialJ Clin Oncol200927111822182819273701
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• Gourgou-BourgadeSBascoul-MolleviCDesseigneFImpact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trialJ Clin Oncol2013311232923213101
   PubMed Web of Science ®Google Scholar
• KrishnanSChadhaASSuhYFocal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiationInt J Radiat Oncol Biol Phys201694475576526972648
   PubMed Web of Science ®Google Scholar